ArticleInfectious diseases and therapy2025
Real-Life Experiences of Herpes Simplex Virus Type 2 Genital Herpes in the United States: A Structured Literature Review and Qualitative Concept Elicitation Study.
Article in Infectious diseases and therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- HSV-2 gE2/gI2 are immune evasion molecules that bind IgG Fc to inhibit antibody-dependent cellular cytotoxicity.Frontiers in immunology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionResearch on real-life experiences of herpes simplex virus type 2 (HSV-2) genital herpes (GH) is scarce. This study primarily aimed to characterize the signs/symptoms and impacts of Ý (HRQoL) of people living with HSV-2 GH in the United States. The secondary aim was to map the identified signs/symptoms and impact concepts onto existing patient-reported outcome (PRO) measures to assess PRO coverage.
methodsA structured literature review and concept elicitation (CE) interviews were conducted based on predefined eligibility criteria. The literature search was conducted across three digital databases and publicly available online resources. The CE interviews were conducted among three participant groups with a confirmed HSV-2 GH diagnosis. A conceptual model was developed based on signs/symptoms and HRQoL impact concepts, identified from the literature review and CE interviews. Key concepts from the model were mapped onto three existing PRO instruments [Herpes Symptoms Checklist (HSC), Herpes Outbreak Impact Questionnaire (HOIQ), and Recurrent Genital Herpes Quality of Life questionnaire (RGHQoL)] to assess concept coverage.
resultsOverall, 26 records were included in the literature review and 30 participants were recruited for CE interviews. The final conceptual model included 35 signs/symptoms and 59 impact concepts categorized among 6 and 9 domains, respectively. Most frequently reported signs/symptoms were itching, sores/lesions/blisters, and body pain. Sores/lesions/blisters were reported as most bothersome. Most frequently reported impact concepts were anxiety and worry, concerns about disclosing diagnosis, and loss of self-esteem/confidence. Conceptual mapping revealed that, when used together, existing PRO instruments provided comprehensive coverage of most concepts (HSC 83%, HOIQ 56%, and RGHQoL 50% of domains covered, respectively).
conclusionsParticipants experienced a range of signs/symptoms and HRQoL impacts. Existing PRO measures provided comprehensive coverage of recurrent HSV-2 GH specific concepts for the domains they measured.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.